Chicago—Adding capecitabine to gemcitabine in adjuvant treatment of pancreatic cancer prolongs survival without increasing toxicity, according to the results of a European Phase III trial presented at the 2016 annual meeting of the American Society of Clinical Oncology (abstract LBA 4006).
Lead investigator John P. Neoptolemos, MD, PhD, said based on these findings, “adjuvant gemcitabine with capecitabine is the standard of care for resected pancreatic cancer.”
The 730-patient